Our Team in the News

BioPlan Associates' Ronald Rader

Ron Rader, Sr. Dir. Technical Research: named Editor-in-Chief of Biopharmaceuticals a new peer-reviewed journal from Landes Bioscience. Biopharmaceuticals is the first and only peer-reviewed journal about biopharmaceuticals. Biopharmaceuticals seeks submission of articles concerning biopharmaceuticals and the industry. Please contact the Editor-in-Chief if interested in submitting an article.

BioPlan Associates' Faiz Kermani PhD

Dr Faiz Kermani, Advisory Board: Has helped establish the "Global Health Education Foundation" (GHEF), a not-for-profit healthcare charity to improve educational resources and training for healthcare professionals in developing countries.
At least 1.3 billion people worldwide lack access to the most basic healthcare. The new non-profit foundation, Global Health Education Foundation, aims to tackle such issues. As President of GHEF, Dr Kermani is supporting the R&D focus of the charity to reduce health disparities among developing countries. In particular, the lack of appropriate educational resources and training opportunities for healthcare professionals. http://www.globalhef.org

BioPlan Associates' Managing Director Eric Langer

Eric Langer, Managing Partner: On Advisory Board of “BioProcess Asia Pacific Conference” July 2010 Singapore.
The Biopharmaceutical market in Asia pacific is growing at a rate among the highest in the globe. This is creating a strong need for production of biopharmaceuticals at higher qualities and volumes. Bioprocess AsiaPacific brings together global leaders within biopharmaceutical industry to explore dynamic strategies, benchmark technologies and analyze sustaining the growth of the industry. http://fleminggulf.com/conference/life-science/BioProcessAsiaPacific.


Customer Needs

Are you asking the right questions?

Peter Drucker

An accurate customer needs analysis helps you make strong, aggressive tactical marketing decisions.

Base your decisions on actual, quantified market requirements. You get up-to-date, relevant information on your customers' (and potential customers') buying patterns, needs, and price sensitivity through our numerous resources and services:

Qualitative vs Quantitative

Many of our clients ask us, "How many people do we need to talk to in order to really quantify the information?"

Our response: "As few as possible to make a smart business decision and reduce the risk associated with making the wrong decision." This keeps budgets in line and maximizes the value of the project. You won't be paying for highly precise information you don't need to make decisions. You won't be paying for "Nice to Know" information—only the information you need to assure you're making the right marketing decisions and investments.

Selecting a Sample Size

  1. Sample size is based on factors such as the number of possible alternative answers and variability of answers among respondents.
  2. Decide if you need a "probability sample"—i.e., data that can be used to project accurately to the entire market segment.
  3. Decide if you have the budget and time to draw a probability sample (so you can calculate confidence limits for sampling error).
  4. Since we often don't know what kind of responses we'll be getting before we implement the study, sample size must often be based on experience.

Very few companies have unlimited budgets for marketing research—neither does yours. Focus on reducing the risks associated with your decision-making, and you may find that you can significantly reduce your sample size. This will make your analysis much more cost-effective!

Questionnaire Do's and Don'ts

—Adapted from Kotler, 11th Ed, P 136